Skip to main content

Advertisement

SpringerLink
Log in

Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstracts

Objectives

The purpose of this study is to evaluate the association of MASCC score (Multinational Association for Supportive Care in Cancer Score) in patients with febrile neutropenia (as resultant treatment of hematological disorders) for risk assessment of morbidity and mortality.

Patients and methods

Patients presenting with Febrile Neutropenia from November 2011 till December 2013 were enrolled in the study. Initially all patients were hospitalized and their MASCC score was calculated, however those with high risk stayed in hospital till full ANC recovery while low risk group was discharged earlier and keenly followed as out-patient while being on prophylactic oral antibiotics. The MASCC risk-index score was calculated and patients with risk score >21 were regarded as low-risk while <21 were labeled as high-risk.

Results

On the basis of 226 febrile neutropenia patient 132(58.4 %) were categorized as low risk while 94(41.5 %) as high risk patients according to MASCC risk index score. In low risk group 123(93 %) had uncomplicated infection while 9(7 %) had complicated infections. There was no mortality documented in low risk group while eight patients died in high risk group.

Conclusion

In this study we correctly predicted outcome of 123(93 %) low risk group patients. The study had positive predictive value of 93 % with both sensitivity and specificity of 65 and 75 % respectively. The MASCC risk score is a valuable tool in determining the outcome in patients with febrile neutropenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23–35

    Article  PubMed  Google Scholar 

  2. Schilling MB, Parks C, Deeter RG (2011) Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2:859–866

    PubMed  PubMed Central  Google Scholar 

  3. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228–237

    Article  PubMed  Google Scholar 

  4. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266

    Article  PubMed  Google Scholar 

  5. Segal BH, Freifeld AG, Baden LR et al (2008) Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw 6:122–174

    Article  Google Scholar 

  6. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (2012) Myeloid Growth Factors. v1

  7. Layman GH, Abella E, Pattengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol/Hematol. doi:10.1016/j.critrevonc.2013.12.006

    Google Scholar 

  8. Klastersky J, Paesmans M, Ruberstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott JA (2000) The Multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051

    Article  CAS  PubMed  Google Scholar 

  9. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52:427–431. doi:10.1093/cid/ciq147

    Article  PubMed  Google Scholar 

  10. Viana LS, Serufo JC, Rocha MOC, Costa RN, Duarte RC (2008) Performances of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 16:841–846

    Article  Google Scholar 

  11. Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the multinational association of supportive care of cancer (MASCC) risk-index score. Support Care Cancer 12(8):555–560

    Article  PubMed  Google Scholar 

  12. Moreau M, Klastersky J, Schwarzbold A, Muanza F, Georgala A, Aoun M et al (2009) A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 20:513–519

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We acknowledge our clinical hematology team for the cooperation in data collection, Ms. Arshi and Dr. Sajjad for the lab support. We are thankful to Miss Sumaira and Miss Sidra for maintaining our database in research department.

Funding

The authors have no support or funding to report.

Author information

Authors and Affiliations

  1. Department of Clinical Hematology and Bone Marrow Transplantation, National Institute of Blood Disease and Bone Marrow Transplantation, ST 2/A Block 17 Gulshan e Iqbal, Sir Shah Suleman Road, KDA Scheme 24, Karachi, Pakistan

    M. Taj, T. Shah, T. Farzana & T. S. Shamsi

  2. Head of Clinical Laboratories, National Institute of Blood Disease and Bone Marrow Transplantation, ST 2/A Block 17 Gulshan e Iqbal, Sir Shah Suleman Road, KDA Scheme 24, Karachi, Pakistan

    M. Nadeem

  3. Department of Research and Development, National Institute of Blood Disease and Bone Marrow Transplantation, ST 2/A Block 17 Gulshan e Iqbal, Sir Shah Suleman Road, KDA Scheme 24, Karachi, Pakistan

    S. Maqsood

Authors
  1. M. Taj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Nadeem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Maqsood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Farzana
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. S. Shamsi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Taj.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taj, M., Nadeem, M., Maqsood, S. et al. Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia. Indian J Hematol Blood Transfus 33, 355–360 (2017). https://doi.org/10.1007/s12288-016-0730-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-016-0730-7

Keywords

Search

Navigation